Market Overview

UPDATE: Deutsche Bank Raises PT to $95 on Gilead Sciences on Latest Data

Share:
Related GILD
Deutsche Bank's Take On Big Pharma: 3 Buys And A Hold
Benzinga's Top Upgrades, Downgrades For June 23, 2017
Too Late To Catch Biotech Rally As Trump Fears Subside? (Investor's Business Daily)

Deutsche Bank reiterated its Buy rating on Gilead Sciences (NASDAQ: GILD) and increased its price target from $75 to $95.

Deutsche Bank said, "At the liver meeting today, Bristol ns5a and GILD nuke showed 100pct SVR with or without ribavirin, in patients that showed up for follow-up. So far 68/82 patients are at SVR12 timeframe and it was noted all 68 were undetectable. While Bristol and Abbott also have regimens with high cure rates, they require more pills (3 drug DAA) and likely will require ribavirin."

Gilead Sciences closed at $73.92 on Monday.

Latest Ratings for GILD

DateFirmActionFromTo
Jun 2017Deutsche BankInitiates Coverage OnBuy
Mar 2017UBSDowngradesBuyNeutral
Feb 2017CitigroupDowngradesBuyNeutral

View More Analyst Ratings for GILD
View the Latest Analyst Ratings

Posted-In: Deutsche BankAnalyst Color Price Target Intraday Update Analyst Ratings

 

Related Articles (GILD)

View Comments and Join the Discussion!